This study focuses on patients with intrahepatic cholangiocarcinoma, a type of bile duct cancer that occurs in the liver and cannot be surgically removed. The treatment approach combines three different medications: durvalumab (an immunotherapy drug that helps the immune system fight cancer cells), cisplatin and gemcitabine (chemotherapy medications), along with a procedure called radioembolization, which delivers radiation directly to liver tumors through blood vessels.
The purpose of this research is to determine how well this combination treatment works and how safe it is for patients with liver-predominant intrahepatic cholangiocarcinoma. The study will evaluate whether tumors respond to the treatment and monitor any side effects that may occur during the therapy.
The treatment plan involves first performing radioembolization, followed by a combination of the three medications given through intravenous infusion. The medications will be administered over a period of six months. Throughout the study, patients will undergo regular medical examinations and imaging tests to monitor their response to treatment and any potential side effects.
Italy 
